When you used to think of Band-Aid bandages and Tylenol, you probably thought of healthcare giant Johnson & Johnson (NYSE: JNJ). That's because the company owned these and other top consumer health products -- at least, it did until recently. This summer, J&J completed its spinoff of its consumer health business, forming a new company called Kenvue (NYSE: KVUE).
This left J&J with two other units -- pharmaceuticals and medtech -- and set Kenvue off on the road to growing the consumer health business independently. Both companies make interesting buys today for their product portfolios and dividend payments. But if you could only choose one of their stocks to buy, which should you go for right now?
J&J built its consumer health segment into an industry giant, but this part of its business still delivered lower growth than its pharmaceuticals and medical technology businesses. For example, consumer health sales rose less than 4% last year, while the other two units each generated sales growth of more than 6%. That unit also represented a smaller share of the revenue picture.
Source Fool.com